Core Viewpoint - The article discusses the significant financing of 2 billion RMB for BrainCo, positioning it as a leading player in the non-invasive brain-computer interface (BCI) sector, contrasting it with Neuralink's invasive approach, highlighting the ongoing technological rivalry in the BCI industry [5][18]. Financing and Growth - BrainCo completed a financing round of approximately 2 billion RMB, led by IDG and Huaden International, making it the second-largest BCI company in terms of funding globally, after Neuralink [5][18]. - Since 2019, BrainCo has completed four financing rounds, accumulating a total of 4.684 billion RMB [15]. Technology Pathways - BrainCo focuses on non-invasive BCI technology, utilizing devices like EEG caps to collect signals, which offers safety and ease of acceptance, while facing challenges in signal precision [6][12]. - Neuralink represents the invasive BCI route, which involves surgical implantation of electrode arrays in the brain, allowing for high-resolution signal collection but poses risks and ethical concerns [5][12]. Product Development and Market Position - BrainCo has developed several products, including smart prosthetics and sleep regulation devices, with some receiving FDA and CE certifications for international sales [6][14]. - The company achieved a milestone in 2022 by producing 100,000 units of a portable high-precision BCI product, breaking the long-standing experimental phase in the industry [14]. Competitive Landscape - The BCI market is characterized by three main technological pathways: invasive, semi-invasive, and non-invasive, each balancing performance, safety, and accessibility differently [20][22]. - Non-invasive BCIs, led by companies like BrainCo, dominate the market, accounting for approximately 82% of the BCI market share, while invasive technologies hold about 18% [22].